CMS Skin Substitute Payment Rate 2026 & Billing Rules

Table of Contents

If your practice bills Medicare Part B for skin substitute products, the math changed this year — significantly. CMS replaced the old product-by-product pricing model with a single flat payment rate, reclassified these products as supplies rather than separately payable biologicals, and tightened the coding rules around them. Practices still working off last year's fee schedule are likely undercharging, overcharging, or exposing themselves to denials without realizing it. Here's what CMS actually finalized for 2026, what it means at the claim level, and how to check your own billing before a payer does it for you.

At a Glance: What You Need to Know

What changed: CMS reclassified most skin substitute products as incident-to supplies, replacing product-specific ASP-based pricing with one national flat rate.
Effective dates: January 1, 2026 for the payment reclassification; April 1, 2026 for new application and product HCPCS codes.
Payment rate: CMS initially finalized approximately $127.28 per square centimeter, then issued a technical correction adjusting the figure to approximately $127.14 per square centimeter, subject to geographic adjustment. Confirm the current rate on your MAC's published fee schedule before billing.
Settings affected: Physician offices / non-facility settings under the Physician Fee Schedule, and hospital outpatient departments under OPPS.
Main billing risk: HCPCS codes that don't match a product's FDA regulatory category, deleted low-cost codes still sitting in the charge master, and inconsistent wound or wastage documentation.
Do this now: Update the charge master, confirm FDA-category-to-HCPCS crosswalks for every product you stock, and audit a sample of recent claims.

What Changed in CMS Skin Substitute Payment Policy for 2026?

For years, Medicare paid for skin substitute products largely the way it pays for many drugs and biologicals: based on each product's average sales price (ASP), plus an add-on percentage. That structure let manufacturer launch prices drive Medicare's payment rate directly, and Part B spending followed. CMS reports that spending on these products grew from about $252 million in 2019 to more than $10 billion in 2024 — an increase CMS attributes largely to rising payment rates and launch prices, not a proportional rise in patients treated.

Starting January 1, 2026, CMS moved most skin substitute products out of that framework. Under the CY 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F), these products are now treated as incident-to supplies when used as part of a covered application procedure, rather than as separately priced biologicals. That distinction matters: incident-to supplies are bundled into a standardized payment instead of being priced product by product.

CMS applied the change across two settings, using consistent methodology in each:

Non-facility (physician office) — billed under the Medicare Physician Fee Schedule (PFS)
Hospital outpatient department — billed under the Hospital Outpatient Prospective Payment System (OPPS)

In both settings, the skin substitute product and the application procedure (CPT codes 15271–15278) are still billed as separate line items — what changed is how the product itself gets priced.

CMS Skin Substitute Payment Rate 2026 Explained

CMS grouped skin substitute products into three categories based on their FDA regulatory pathway: 361 HCT/Ps (human cells, tissues, and cellular and tissue-based products), 510(k)-cleared devices, and PMA-approved products. Rather than pricing each category separately in the first year, CMS finalized a single payment rate reflecting the highest average across all three — reasoning that this avoids underestimating the resources involved in furnishing these products.

The rate CMS originally published was approximately $127.28 per square centimeter. CMS then issued a technical correction adjusting that figure to approximately $127.14 per square centimeter. CMS has also indicated it intends to propose category-specific rates in future rulemaking, so this is very likely to change again — treat today's rate as current, not permanent.

Who Is Most Affected by the 2026 Changes?

This reclassification touches anyone billing Medicare Part B for skin substitute application: wound care physicians and wound centers, dermatology practices, podiatry groups, hospital outpatient departments, and ambulatory settings treating chronic wounds, diabetic ulcers, and burns. Billers and coders across these specialties feel it most directly — fee schedules, HCPCS crosswalks, and charge master entries all need to be rebuilt around the new categories rather than adjusted line by line.

2026 Skin Substitute Coding and Billing Considerations

Getting paid correctly under the new structure depends on more than knowing the new rate. Confirm each of the following on every claim:

HCPCS code accuracy — the product code billed must match the product's current FDA regulatory category (361 HCT/P, 510(k), or PMA).
Application coding — CPT codes 15271–15278 remain the application codes across settings and were not changed by this rule.
Units and square centimeters — document the exact wound surface area treated, separate from any product surface area that was opened but not applied.
Wastage documentation — where part of a product is discarded, standard modifier conventions (JW for discarded amounts, JZ to confirm zero waste) still apply and should be supported by the clinical note.
Place of service — confirm the POS code matches where the application actually occurred.
Medical necessity and diagnosis linkage — the wound diagnosis, conservative-care history, and clinical rationale should be clearly documented and linked to the procedure.
Payer-specific rules — check current Medicare Administrative Contractor (MAC) policy in your jurisdiction, since some Local Coverage Determinations affecting skin substitutes have been withdrawn or revised.
Claim edits — watch for edits tied to the deleted low-cost C-codes; claims still using them will be rejected outright.

April 1, 2026 Skin Substitute Code Changes

Separate from the January 1 payment reclassification, CMS created new HCPCS Level II codes effective April 1, 2026, as part of its regular quarterly OPPS update. These include new application codes for non-sheet form skin substitute products (HCPCS G0681–G0684), assigned status indicator N — meaning the application is packaged rather than paid separately under OPPS. CMS also created new product-specific HCPCS codes, assigned to APC 6001 (510(k) Skin Substitute Products) or APC 6002 (361 HCT/P Skin Substitute Products) under status indicator S1, meaning these products remain separately payable under OPPS.

Don't conflate the two dates. January 1, 2026 changed how skin substitute products are paid and classified. April 1, 2026 added new codes inside that already-changed framework — it wasn't a second policy overhaul.

7 Common Skin Substitute Billing Errors That Can Trigger Denials

Billing a deleted low-cost C-code (C5271–C5278) that's still sitting in the charge master.
A mismatch between the HCPCS code billed and the product's actual FDA regulatory category.
Wound measurements that don't match between the clinical note and the submitted claim.
Missing or inconsistent documentation of discarded product for JW/JZ modifier use.
Diagnosis codes that don't clearly support medical necessity for the application billed.
An incorrect place-of-service code relative to where the application actually occurred.
Relying on last year's fee schedule, or an outdated internal rate card, instead of the current CMS/MAC-published rate.

2026 Skin Substitute Billing Compliance Checklist

Use this as a working checklist during your next internal review:

Charge master updated to remove deleted C-codes (C5271–C5278)
Every skin substitute product cross-walked to its current HCPCS code and FDA regulatory category
Fee schedule reflects the CMS/MAC-published 2026 rate, not the originally proposed figure
Wound size documentation separated clearly from any discarded product amount
JW/JZ modifier usage supported by documentation on every applicable claim
Place-of-service codes verified against where the application actually occurred
A sample of recent claims audited against the new payment and coding framework
Staff briefed on the April 1, 2026 application code additions (G0681–G0684)

CMS Skin Substitute Billing — Before vs. After 2026

Aspect	Before 2026	2026 and After
Product pricing	Individual ASP-based pricing per product	Single flat national rate across most products
Classification	Primarily by brand/manufacturer	By FDA regulatory pathway (361 HCT/P, 510(k), PMA)
Low-cost codes	C5271–C5278 in active use	Deleted; claims using them are rejected
Rate stability	Rate varied significantly by product	One rate today, with category-specific rates signaled for future years
Application codes	CPT 15271–15278	Unchanged, plus new G0681–G0684 (non-sheet form, effective April 1, 2026)

How a Medical Billing Audit Can Identify Skin Substitute Revenue and Compliance Issues

A policy change this size rarely announces itself through one denied claim. It shows up gradually — a slightly lower reimbursement here, a records request there — until the pattern becomes expensive. A focused billing audit typically reviews:

Coding accuracy against current HCPCS-to-FDA-category crosswalks
Claim-level payment variance against the current published rate
Denial trends tied specifically to skin substitute claims
Documentation consistency between clinical notes and submitted claims
Accounts receivable aging for skin substitute-related claims
Payer-specific patterns, including MAC and commercial payer differences
Potential underpayments from claims still priced off outdated fee schedules
Workflow gaps that let deleted or mismatched HCPCS codes reach a claim

We recommend reviewing a sample of recent claims now, before a payer's own audit surfaces the same issues on less favorable terms.

How Sirius Solutions Global Helps Providers Strengthen Billing Compliance

Sirius Solutions Global works with practices on the revenue cycle side of billing — coding accuracy, claim scrubbing, denial management, and accounts receivable follow-up. For practices navigating the 2026 skin substitute changes, our billing team can review your current charge master, check your HCPCS-to-FDA-category mapping, and help flag claims that may be at risk under the new payment structure. Recommendations are based on your actual billing data and current CMS guidance, not assumptions about your payer mix.

Review your billing workflow before avoidable errors become costly denials.

Get Your Free Billing Audit →

Frequently Asked Questions

CMS finalized a single national rate of approximately $127.28 per square centimeter, later corrected to approximately $127.14 per square centimeter, for most skin substitute products used in a covered application procedure. Confirm the current published rate with your MAC, since CMS has signaled that future years may bring category-specific rates.

Yes. CMS reclassified most skin substitute products from separately payable, ASP-priced biologicals to incident-to supplies bundled with the application procedure.

The payment reclassification took effect January 1, 2026. Additional HCPCS codes for non-sheet form product application (G0681–G0684) and new product-specific codes took effect April 1, 2026, as part of CMS's regular quarterly update.

Yes. CMS applied the reclassification to both non-facility settings under the Physician Fee Schedule and hospital outpatient departments under OPPS.

Update charge masters to remove deleted codes, confirm every product's HCPCS-to-FDA-category crosswalk, verify your fee schedule reflects the current CMS/MAC-published rate, and tighten wound and wastage documentation.

Yes. Mismatched wound measurements, unsupported wastage modifiers, and diagnosis codes that don't support medical necessity are among the most common denial triggers under the new framework.

Given the scope of this change, a focused audit of recent claims is a reasonable precaution — it's far less costly to correct a coding or documentation gap internally than to respond to a payer audit after the fact.

Disclaimer: Medicare payment rates, coding requirements, and coverage policies described in this article reflect CMS guidance available at the time of publication and are subject to change. This article is provided for general informational purposes and does not constitute billing, coding, legal, or reimbursement advice for any specific claim. Providers should verify current CMS and Medicare Administrative Contractor (MAC) guidance, along with any applicable payer-specific policies, before submitting claims.

Sources & References

CMS — Calendar Year (CY) 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F), fact sheet, cms.gov
CMS — Calendar Year 2026 Hospital Outpatient Prospective Payment System / ASC Final Rule, fact sheet, cms.gov
CMS — Skin Substitutes payment resource page, cms.gov
CMS MLN Matters MM14315 — Medicare Physician Fee Schedule Final Rule Summary: CY 2026
CMS MLN Matters MM14380 — Hospital Outpatient Prospective Payment System: April 2026 Update
Federal Register — Correction notice to the CY 2026 Physician Fee Schedule Final Rule (Nov. 28, 2025)

CMS Skin Substitute Payment Rate 2026: Is Your Billing Compliant With the New Medicare Rules?